Earnings Report·April 29, 2026
Biogen (NASDAQ: BIIB) Surges 6% on Q1 Sales Sweep and Alzheimer's Momentum
Biogen jumped 6% after delivering a strong Q1 with broad-based product sales growth, led by Alzheimer's disease franchises.
Biogen Inc. (NASDAQ: BIIB) Stock News & Analysis
Biogen Inc. (NASDAQ: BIIB) is a company in the Health Care sector, listed on the NASDAQ. This page collects all Alpha Stocks Insight coverage of BIIB: earnings reports, analyst actions, and company news, updated as new articles are published. 3 articles since April 29, 2026.
BIIB Coverage -- 3 Articles
Health Care·May 15, 2026
Biogen Inc. (NASDAQ: BIIB) Advances Phase 2 Tau Alzheimer's Study
Biogen progresses Phase 2 tau study targeting multiple Alzheimer's pathologies, highlighted by ADDF at research conference.
2 min readRead article
Earnings Report·April 29, 2026
Biogen (NASDAQ: BIIB) Wallops Q1 Estimates, Cuts Full-Year Profit Guidance
Biogen shares rose 1.50% after beating Q1 revenue estimates, but management slashed full-year adjusted EPS guidance to $14.25–$15.25, signaling caution ahead.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.